Filing Details
- Accession Number:
- 0001172661-24-001209
- Form Type:
- 13G Filing
- Publication Date:
- 2024-02-13 19:00:00
- Filed By:
- Rock Springs Capital Management
- Company:
- Mereo Biopharma Group Plc
- Filing Date:
- 2024-02-14
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Rock Springs Capital Management | 0 | 39,919,255 | 0 | 39,919,255 | 39,919,255 | 6.38% |
| Rock Springs Capital Master Fund | 0 | 31,454,710 | 0 | 31,454,710 | 31,454,710 | 5.03% |
| Rock Springs Capital | 0 | 39,919,255 | 0 | 39,919,255 | 39,919,255 | 6.38% |
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
MEREO BIOPHARMA GROUP PLC
| (Name of Issuer) |
|
Ordinary Shares, nominal value £0.003, per ordinary share |
| (Title of Class of Securities) |
589492107** |
| (CUSIP Number) |
|
|
| July 3, 2023 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
**There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 589492107 has been assigned to the American Depositary Receipts (“ADRs”) of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “MREO.” Each ADR represents 5 Ordinary Shares.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).